

Consonus Pharmacy is just one week away from celebrating the completion of all vaccine clinics! As we celebrate this milestone, we are actively planning the vaccine continuity phase together to maintain the reduction in COVID positivity rates. We will keep you updated on this topic as well as share the latest clinical updates.

Q: What is the latest guidance around vaccinated people who subsequently develop COVID-19?

A: For vaccinated people who subsequently experience COVID-19, prior receipt of a COVID-19 vaccine should not affect treatment decisions (including use of monoclonal antibodies, convalescent plasma, antiviral treatment, or corticosteroid administration) or timing of such treatments.

If a person is fully vaccinated (i.e., ≥ 2 weeks after completion of a two-dose mRNA series or single dose of Janssen vaccine) and tests positive for SARS-CoV-2, healthcare providers and local health departments are encouraged to request the specimen be held and to report the case to their state health department. CDC will work with the state to collect information about the case. In addition, information about these cases should be reported to VAERS.

Q: What are the updated recommendations related to vaccination timing for immunocompromised people?

A: Immunocompromised people can receive COVID-19 vaccination. Based on general best practices for vaccination of immunocompromised people, ideally COVID-19 vaccination should be completed at least two weeks before initiation of immunosuppressive therapies. When it is not possible to administer a complete COVID-19 vaccine series in advance, people on immunosuppressive therapy can still receive COVID-19 vaccination. Decisions to delay immunosuppressive therapy to complete COVID-19 vaccination should consider the person's risks related to their underlying condition.

Q: With the decline in COVID-19 positivity rates, is bamlanivimab for treatment still available at Consonus?

A: Yes. However, evaluations of effectiveness are ongoing for the use of bamlanivimab in regions where the SARS-CoV2 mutation(20C/CAL.20C) is circulating in high numbers given concerns that the clinical activity of bamlanivimab is impacted by this variant. This affects the states of California, Arizona, and Nevada. The other two authorized combination products, bamlanivimab + etesevimab and casirivimab + imdevimab, do not appear to be affected. We can order etesevimab to compliment bamlanivmab if there is a need.